Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Enhanced radiosensitivity of androgen-resistant prostate cancer: AZD1152-mediated Aurora kinase B inhibition.

Niermann KJ, Moretti L, Giacalone NJ, Sun Y, Schleicher SM, Kopsombut P, Mitchell LR, Kim KW, Lu B.

Radiat Res. 2011 Apr;175(4):444-51. doi: 10.1667/RR2317.1. Epub 2011 Jan 11.

PMID:
21222513
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Enhancement of radiation response in p53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152.

Tao Y, Zhang P, Girdler F, Frascogna V, Castedo M, Bourhis J, Kroemer G, Deutsch E.

Oncogene. 2008 May 22;27(23):3244-55. Epub 2007 Dec 17.

PMID:
18084327
[PubMed - indexed for MEDLINE]
3.

MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation.

Moretti L, Niermann K, Schleicher S, Giacalone NJ, Varki V, Kim KW, Kopsombut P, Jung DK, Lu B.

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1189-97. doi: 10.1016/j.ijrobp.2011.01.060. Epub 2011 Apr 20.

PMID:
21514073
[PubMed - indexed for MEDLINE]
4.

Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity.

Konsoula Z, Cao H, Velena A, Jung M.

Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1541-8. doi: 10.1016/j.ijrobp.2010.11.057. Epub 2011 Jan 27.

PMID:
21277099
[PubMed - indexed for MEDLINE]
5.

The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.

Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, Noguchi N, Kudo A, Nakamura N, Ito K, Arii S.

J Hepatol. 2010 Jan;52(1):63-71. doi: 10.1016/j.jhep.2009.10.013. Epub 2009 Oct 29.

PMID:
19913935
[PubMed - indexed for MEDLINE]
6.

The FLT3 internal tandem duplication mutation is a secondary target of the aurora B kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells.

Grundy M, Seedhouse C, Shang S, Richardson J, Russell N, Pallis M.

Mol Cancer Ther. 2010 Mar;9(3):661-72. doi: 10.1158/1535-7163.MCT-09-1144. Epub 2010 Feb 16.

PMID:
20159992
[PubMed - indexed for MEDLINE]
Free Article
7.

Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3.

Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ, Wang PS.

J Cell Biochem. 2007 May 1;101(1):44-56.

PMID:
17340628
[PubMed - indexed for MEDLINE]
8.

Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: role of reactive oxygen species, GSH and Nrf2 in radiosensitivity.

Jayakumar S, Kunwar A, Sandur SK, Pandey BN, Chaubey RC.

Biochim Biophys Acta. 2014 Jan;1840(1):485-94. doi: 10.1016/j.bbagen.2013.10.006. Epub 2013 Oct 9.

PMID:
24121106
[PubMed - indexed for MEDLINE]
9.

The Akt-inhibitor Erufosine induces apoptotic cell death in prostate cancer cells and increases the short term effects of ionizing radiation.

Rudner J, Ruiner CE, Handrick R, Eibl HJ, Belka C, Jendrossek V.

Radiat Oncol. 2010 Nov 16;5:108. doi: 10.1186/1748-717X-5-108.

PMID:
21080918
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe.

Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, Varna M, Opolon P, Castedo M, Bourhis J, Kroemer G, Deutsch E.

Cell Cycle. 2009 Oct 1;8(19):3172-81. Epub 2009 Oct 4.

PMID:
19755861
[PubMed - indexed for MEDLINE]
Free Article
11.

Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.

Ohneseit PA, Krebiehl G, Dittmann K, Kehlbach R, Rodemann HP.

Radiother Oncol. 2007 Feb;82(2):229-38. Epub 2007 Jan 4.

PMID:
17207548
[PubMed - indexed for MEDLINE]
12.

Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.

Isebaert SF, Swinnen JV, McBride WH, Haustermans KM.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):239-47. doi: 10.1016/j.ijrobp.2011.03.030.

PMID:
21816290
[PubMed - indexed for MEDLINE]
13.

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer.

Gully CP, Zhang F, Chen J, Yeung JA, Velazquez-Torres G, Wang E, Yeung SC, Lee MH.

Mol Cancer. 2010 Feb 22;9:42. doi: 10.1186/1476-4598-9-42.

PMID:
20175926
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Aurora kinase inhibitor AZD1152 negatively affects the growth and survival of HTLV-1-infected T lymphocytes in vitro.

Tomita M, Tanaka Y, Mori N.

Int J Cancer. 2010 Oct 1;127(7):1584-94. doi: 10.1002/ijc.25178. Retraction in: Int J Cancer. 2011 Dec 1;129(11):2762-3.

PMID:
20091867
[PubMed - indexed for MEDLINE]
15.

Epothilone B confers radiation dose enhancement in DAB2IP gene knock-down radioresistant prostate cancer cells.

Kong Z, Raghavan P, Xie D, Boike T, Burma S, Chen D, Chakraborty A, Hsieh JT, Saha D.

Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1210-8. doi: 10.1016/j.ijrobp.2010.06.019.

PMID:
20970033
[PubMed - indexed for MEDLINE]
16.

Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines.

Sak A, Stuschke M, Groneberg M, Kübler D, Pöttgen C, Eberhardt WE.

Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):492-9. doi: 10.1016/j.ijrobp.2011.12.021. Epub 2012 Feb 28.

PMID:
22381900
[PubMed - indexed for MEDLINE]
17.

The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.

Sun Y, St Clair DK, Fang F, Warren GW, Rangnekar VM, Crooks PA, St Clair WH.

Mol Cancer Ther. 2007 Sep;6(9):2477-86.

PMID:
17876045
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Radiosensitization of tumour cells by cantharidin and some analogues.

Price WA, Stobbe CC, Park SJ, Chapman JD.

Int J Radiat Biol. 2004 Apr;80(4):269-79.

PMID:
15204704
[PubMed - indexed for MEDLINE]
19.

Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.

Yano S, Matsuyama H, Hirata H, Inoue R, Matsumoto H, Ohmi C, Miura K, Shirai M, Iizuka N, Naito K.

Oncol Rep. 2006 Jun;15(6):1453-60.

PMID:
16685379
[PubMed - indexed for MEDLINE]
20.

5-aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cells.

Isebaert SF, Swinnen JV, McBride WH, Begg AC, Haustermans KM.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1515-23. doi: 10.1016/j.ijrobp.2011.06.1964. Epub 2011 Sep 21.

PMID:
21944462
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk